Protalix BioTherapeutics, Inc. (PLX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 30M 60M 90M Q4 '10: 6.6M Q1 '11: 9.6M Q2 '11: 9.3M Q3 '11: 7.2M Q4 '11: 8.4M Q1 '12: 8.1M Q2 '12: 33.5M Q3 '12: 36.1M Q4 '12: 34.9M Q1 '13: 34.6M Q2 '13: 10.7M Q3 '13: 9.3M Q4 '15: 4.4M Q1 '16: 3.4M Q2 '16: 3.8M Q3 '16: 7.1M Q4 '16: 9.2M Q1 '17: 11.4M Q2 '17: 16M Q3 '17: 18.9M Q4 '17: 21.1M Q1 '18: 22.7M Q2 '18: 18.4M Q3 '18: 11.5M Q4 '18: 34.2M Q1 '19: 40.1M Q2 '19: 50.4M Q3 '19: 64M Q4 '19: 54.7M Q1 '20: 65.9M Q2 '20: 64.6M Q3 '20: 61.2M Q4 '20: 62.9M Q1 '21: 52.6M Q2 '21: 48M Q3 '21: 49.3M Q4 '21: 38.4M Q1 '22: 43.1M Q2 '22: 45.4M Q3 '22: 47.6M Q4 '22: 47.6M Q1 '23: 41.1M Q2 '23: 67.5M Q3 '23: 63.6M Q4 '23: 65.5M Q1 '24: 59.7M Q2 '24: 38.1M Q3 '24: 45.7M Q4 '24: 53.4M Q1 '25: 59.8M Q2 '25: 61.9M Q3 '25: 61.8M Q4 '25: 52.7M Q1 '26: 76.4M Q2 '26: 80.6M Q1 '12 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Gross Profit TTM

-10M 0 10M 20M 30M Q4 '10: 6.9M Q1 '11: 11.2M Q2 '11: 5.9M Q3 '11: 4.4M Q4 '11: 1.4M Q1 '12: -1.4M Q2 '12: 25.4M Q3 '12: 27.7M Q4 '12: 26.3M Q1 '13: 26.9M Q2 '13: 6.6M Q3 '13: 5.4M Q4 '15: 3.6M Q1 '16: 2.4M Q2 '16: 1.4M Q3 '16: 672K Q4 '16: 801K Q1 '17: 1.4M Q2 '17: 2.2M Q3 '17: 3.2M Q4 '17: 4M Q1 '18: 4.8M Q2 '18: 3.8M Q3 '18: 1.1M Q2 '11 Q1 '12 Q4 '12 Q3 '13 Q2 '16 Q1 '17 Q4 '17 Q3 '18

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q4 '10: -30M Q1 '11: -26.9M Q2 '11: -30.6M Q3 '11: -36.5M Q4 '11: -36.5M Q1 '12: -37.6M Q2 '12: -14.1M Q3 '12: -10.9M Q4 '12: -12.2M Q1 '13: -10.5M Q2 '13: -27.1M Q3 '13: -27.1M Q4 '13: -34.1M Q1 '14: -36.1M Q2 '14: -34.7M Q3 '14: -35.2M Q4 '14: -28.6M Q1 '15: -27.5M Q2 '15: -27.6M Q3 '15: -26.4M Q4 '15: -23.7M Q1 '16: -26.1M Q2 '16: -30.5M Q3 '16: -32.1M Q4 '16: -33.2M Q1 '17: -31.7M Q2 '17: -32.5M Q3 '17: -33.7M Q4 '17: -34.5M Q1 '18: -33.3M Q2 '18: -29.2M Q3 '18: -25.2M Q4 '18: -19.3M Q1 '19: -19.7M Q2 '19: -18.8M Q3 '19: -16.6M Q4 '19: -10.7M Q1 '20: -490K Q2 '20: 3.1M Q3 '20: 2.1M Q4 '20: 2.7M Q1 '21: -5.7M Q2 '21: -12.6M Q3 '21: -11.9M Q4 '21: -20.5M Q1 '22: -18.6M Q2 '22: -15M Q3 '22: -16.2M Q4 '22: -13M Q1 '23: -13.6M Q2 '23: 12.3M Q3 '23: 13.6M Q4 '23: 10.5M Q1 '24: 8.1M Q2 '24: -14.8M Q3 '24: -8.9M Q4 '24: 3.9M Q1 '25: 4.6M Q2 '25: 8.2M Q3 '25: 6.4M Q4 '25: -5.5M Q1 '26: 19.8M Q2 '26: 23.3M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q4 '10: -29M Q1 '11: -26.1M Q2 '11: -29.7M Q3 '11: -36.1M Q4 '11: -36.5M Q1 '12: -37.4M Q2 '12: -14.1M Q3 '12: -10.7M Q4 '12: -11.6M Q1 '13: -10M Q2 '13: -26.5M Q3 '13: -26.8M Q4 '13: -27.8M Q1 '14: -30.8M Q2 '14: -30.1M Q3 '14: -32.4M Q4 '14: -29.9M Q1 '15: -28.6M Q2 '15: -27.5M Q3 '15: -23.3M Q4 '15: 58M Q1 '16: 55.4M Q2 '16: 49.6M Q3 '16: 46.2M Q4 '16: -29.4M Q1 '17: -79.9M Q2 '17: -68.6M Q3 '17: -72.8M Q4 '17: -83.4M Q1 '18: -31.5M Q2 '18: -40.4M Q3 '18: -34.3M Q4 '18: -26.5M Q1 '19: -26.5M Q2 '19: -25.8M Q3 '19: -24M Q4 '19: -18.3M Q1 '20: -9.3M Q2 '20: -5.8M Q3 '20: -6.6M Q4 '20: -6.5M Q1 '21: -13.7M Q2 '21: -20.8M Q3 '21: -20.5M Q4 '21: -27.6M Q1 '22: -24.4M Q2 '22: -18.5M Q3 '22: -17.9M Q4 '22: -14.9M Q1 '23: -15.8M Q2 '23: 8.9M Q3 '23: 10.6M Q4 '23: 8.3M Q1 '24: 6.8M Q2 '24: -14.7M Q3 '24: -9.6M Q4 '24: 2.9M Q1 '25: 3.9M Q2 '25: 6.3M Q3 '25: 5.4M Q4 '25: -6.6M Q1 '26: 15.3M Q2 '26: 18.9M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

0 15M 30M 45M Q4 '11: 1.5M Q1 '12: 2.1M Q2 '12: 5.2M Q3 '12: 7.4M Q4 '12: 8.1M Q1 '13: 7.8M Q2 '13: 5.8M Q3 '13: 5.1M Q4 '15: 730K Q1 '16: 971K Q2 '16: 2.4M Q3 '16: 6.4M Q4 '16: 8.4M Q1 '17: 10M Q2 '17: 13.8M Q3 '17: 15.6M Q4 '17: 15.2M Q1 '18: 16.1M Q2 '18: 12.7M Q3 '18: 8.6M Q4 '18: 9.3M Q1 '19: 8.4M Q2 '19: 8.9M Q3 '19: 10.2M Q4 '19: 10.9M Q1 '20: 12.3M Q2 '20: 11.4M Q3 '20: 11.1M Q4 '20: 10.9M Q1 '21: 12.2M Q2 '21: 15.1M Q3 '21: 16M Q4 '21: 16.3M Q1 '22: 17.6M Q2 '22: 17M Q3 '22: 20.3M Q4 '22: 19.6M Q1 '23: 16.6M Q2 '23: 18.7M Q3 '23: 16.5M Q4 '23: 23M Q1 '24: 22.5M Q2 '24: 25.8M Q3 '24: 29.3M Q4 '24: 24.3M Q1 '25: 29.9M Q2 '25: 26.3M Q3 '25: 26.3M Q4 '25: 27M Q1 '26: 22.9M Q2 '26: 24.8M Q1 '12 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q2 '11: -26.5M Q3 '11: -25M Q4 '11: -23.6M Q1 '12: -25.9M Q2 '12: -7.9M Q3 '12: -7.8M Q4 '12: 635K Q1 '13: -2.7M Q2 '13: -23.9M Q3 '13: -24.1M Q4 '13: -30.7M Q1 '14: -29.4M Q2 '14: -27.8M Q3 '14: -29.1M Q4 '14: -29.1M Q1 '15: -27.2M Q2 '15: -26M Q3 '15: -25.1M Q4 '15: -24.3M Q1 '16: -27.5M Q2 '16: -33.8M Q3 '16: -28.6M Q4 '16: -32.1M Q1 '17: -30.9M Q2 '17: -27.8M Q3 '17: -34.9M Q4 '17: -10M Q1 '18: -11M Q2 '18: -10.3M Q3 '18: 13.9M Q4 '18: -7.7M Q1 '19: -5.6M Q2 '19: -2.8M Q3 '19: -19.7M Q4 '19: -19.4M Q1 '20: -19.2M Q2 '20: -21.9M Q3 '20: -22.2M Q4 '20: -26.1M Q1 '21: -28.8M Q2 '21: -14.5M Q3 '21: -12.7M Q4 '21: -10.3M Q1 '22: -6.3M Q2 '22: -20.2M Q3 '22: -27.5M Q4 '22: -25M Q1 '23: -22.2M Q2 '23: -9.8M Q3 '23: -7.5M Q4 '23: -1.3M Q1 '24: 5.9M Q2 '24: -2.7M Q3 '24: 8.3M Q4 '24: 8.7M Q1 '25: -572K Q2 '25: -2.2M Q3 '25: -10M Q4 '25: -12M Q1 '26: 15.1M Q2 '26: 9.9M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q2 '11: -32.9M Q3 '11: -31M Q4 '11: -29.3M Q1 '12: -29.8M Q2 '12: -10.7M Q3 '12: -10.3M Q4 '12: -1.4M Q1 '13: -4.6M Q2 '13: -26.3M Q3 '13: -26M Q4 '13: -32.5M Q1 '14: -30.9M Q2 '14: -28.7M Q3 '14: -30M Q4 '14: -29.9M Q1 '15: -27.8M Q2 '15: -26.8M Q3 '15: -25.8M Q4 '15: -24.7M Q1 '16: -28.1M Q2 '16: -34.5M Q3 '16: -29.4M Q4 '16: -32.9M Q1 '17: -31.7M Q2 '17: -28.6M Q3 '17: -35.7M Q4 '17: -11M Q1 '18: -12M Q2 '18: -11.1M Q3 '18: 13.1M Q4 '18: -8.4M Q1 '19: -6.2M Q2 '19: -3.3M Q3 '19: -20.5M Q4 '19: -20M Q1 '20: -19.7M Q2 '20: -22.6M Q3 '20: -22.7M Q4 '20: -26.8M Q1 '21: -29.8M Q2 '21: -15.5M Q3 '21: -14M Q4 '21: -11.7M Q1 '22: -7.6M Q2 '22: -21.3M Q3 '22: -28.3M Q4 '22: -25.6M Q1 '23: -22.8M Q2 '23: -10.6M Q3 '23: -8.6M Q4 '23: -2.5M Q1 '24: 4.4M Q2 '24: -4.2M Q3 '24: 7.2M Q4 '24: 7.4M Q1 '25: -1.6M Q2 '25: -3.4M Q3 '25: -11.7M Q4 '25: -13.6M Q1 '26: 13M Q2 '26: 7.7M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '11: 85.6M Q2 '12: 94.9M Q2 '13: 92.3M Q2 '16: 99.8M Q2 '17: 192.6M Q2 '18: 146.6M Q3 '20: 32.9M Q1 '21: 39.9M Q2 '21: 45.4M Q3 '21: 45.6M Q1 '22: 45.8M Q2 '22: 47.3M Q3 '22: 49.5M Q1 '23: 57.5M Q2 '23: 83.2M Q3 '23: 83.8M Q1 '24: 73M Q2 '24: 73.3M Q3 '24: 81.2M Q1 '25: 76.6M Q2 '25: 81.3M Q3 '25: 80.8M Q1 '26: 83M Q2 '26: 82.6M Q2 '13 Q2 '18 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '10: -0.36 Q1 '11: -0.40 Q2 '11: -0.68 Q3 '11: -0.81 Q4 '11: -0.60 Q1 '12: -0.59 Q2 '12: -0.33 Q3 '12: -0.17 Q4 '12: 0.08 Q1 '13: 0.06 Q2 '13: -0.11 Q3 '13: -0.23 Q4 '13: -0.20 Q1 '14: -0.17 Q2 '14: -0.17 Q3 '14: -0.20 Q4 '14: -0.17 Q1 '15: -0.31 Q2 '15: -0.29 Q3 '15: -0.24 Q4 '15: 0.62 Q1 '16: 0.59 Q2 '16: 0.53 Q3 '16: 0.50 Q4 '16: -0.29 Q1 '17: -0.68 Q2 '18: -6.02 Q3 '18: -5.97 Q4 '18: -0.55 Q1 '19: -1.00 Q2 '19: -1.46 Q3 '19: -1.66 Q4 '19: -1.24 Q1 '20: -0.64 Q2 '20: -0.25 Q3 '20: -0.15 Q4 '20: -0.22 Q1 '21: -0.46 Q2 '21: -0.58 Q3 '21: -0.53 Q4 '21: -0.62 Q1 '22: -0.53 Q2 '22: -0.39 Q3 '22: -0.37 Q4 '22: -0.30 Q1 '23: -0.30 Q2 '23: 0.02 Q3 '23: 0.05 Q4 '23: 0.09 Q1 '24: 0.08 Q2 '24: -0.16 Q3 '24: -0.09 Q4 '24: 0.04 Q1 '25: 0.05 Q2 '25: 0.08 Q3 '25: 0.08 Q4 '25: -0.09 Q1 '26: 0.18 Q2 '26: 0.23 Q2 '11 Q2 '13 Q2 '15 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.